← Back to Clinical Trials
Recruiting NCT07051655

NCT07051655 The Effects of Exogenous Ketones on Cognitive Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07051655
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition Placebo - Control
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2025-12-01
Primary Completion 2027-07-31

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Ketone Monoester (KE)Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2025-12-01 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the acute effects of exogenous ketone monoester (KME) supplementation on cognitive function in three groups of adults aged 19-55 years: (1) obese, sedentary individuals; (2) lean, sedentary individuals; and (3) lean individuals who engage in regular physical activity (e.g., collegiate or amateur athletes). The main questions it aims to answer are to: * Assess the effects of acute KME supplementation versus placebo on cognitive, sensorimotor, and functional outcomes within groups. * Compare cognitive performance across the three groups. The primary outcome is cognitive performance assessed using the NIH Toolbox Cognition Battery. Secondary Outcomes include sensorimotor performance, measured using the Senaptec Sensory System, and driving performance, assessed with a driving simulator.

Eligibility Criteria

Inclusion Criteria: * Age 19-55 years * BMI 30-40 (obese group) or 18-25 (lean and athlete groups) * Sedentary status (\<2 hrs/week of structured physical activity) for obese and lean groups * Active athlete status (≥5 days/week of structured activity) for athlete group Exclusion Criteria: * Diagnosed neurological conditions (e.g., Parkinson's disease, multiple sclerosis, schizophrenia, muscular dystrophy, stroke, cerebral palsy) * History of seizures * Use of medications for diabetes, mood disorders, or attention disorders * Pregnant or breastfeeding * Current or recent use (within 1 month) of exogenous ketone supplements or adherence to a ketogenic diet

Contact & Investigator

Central Contact

Sarah K Sweatt, PhD

✉ sksweatt@uab.edu

📞 205-975-5398

Frequently Asked Questions

Who can join the NCT07051655 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, up to 55 Years, studying Placebo - Control. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07051655 currently recruiting?

Yes, NCT07051655 is actively recruiting participants. Contact the research team at sksweatt@uab.edu for enrollment information.

Where is the NCT07051655 trial being conducted?

This trial is being conducted at Birmingham, United States.

Who is sponsoring the NCT07051655 clinical trial?

NCT07051655 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 45 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology